Goldman Sachs Group Inc. purchased a new position in AnaptysBio Inc (NASDAQ:ANAB) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 11,569 shares of the biotechnology company’s stock, valued at approximately $277,000. Goldman Sachs Group Inc. owned about 0.06% of AnaptysBio as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in shares of AnaptysBio by 22.6% during the 2nd quarter. Vanguard Group Inc. now owns 206,031 shares of the biotechnology company’s stock valued at $4,931,000 after buying an additional 37,932 shares during the period. Northern Trust Corp lifted its holdings in shares of AnaptysBio by 360.6% during the 2nd quarter. Northern Trust Corp now owns 60,042 shares of the biotechnology company’s stock valued at $1,436,000 after buying an additional 47,005 shares during the period. Artal Group S.A. lifted its holdings in shares of AnaptysBio by 459.4% during the 2nd quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock valued at $5,983,000 after buying an additional 205,310 shares during the period. New York State Common Retirement Fund bought a new position in shares of AnaptysBio during the 2nd quarter valued at $168,000. Finally, TIAA CREF Investment Management LLC lifted its holdings in shares of AnaptysBio by 69.2% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 13,844 shares of the biotechnology company’s stock valued at $331,000 after buying an additional 5,663 shares during the period. Institutional investors own 75.48% of the company’s stock.
Shares of AnaptysBio Inc (NASDAQ ANAB) traded up $1.03 during trading hours on Monday, hitting $85.42. 269,038 shares of the company were exchanged, compared to its average volume of 210,110. The company has a quick ratio of 10.77, a current ratio of 10.77 and a debt-to-equity ratio of 0.09. AnaptysBio Inc has a 1 year low of $15.17 and a 1 year high of $88.17.
AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.47) by $0.02. sell-side analysts forecast that AnaptysBio Inc will post -1.72 earnings per share for the current year.
A number of brokerages recently commented on ANAB. Zacks Investment Research raised AnaptysBio from a “hold” rating to a “buy” rating and set a $36.00 target price on the stock in a report on Wednesday, September 13th. Wedbush reaffirmed an “outperform” rating and issued a $75.00 target price (up from $37.00) on shares of AnaptysBio in a report on Friday, October 13th. Jefferies Group began coverage on AnaptysBio in a report on Thursday, November 9th. They issued a “buy” rating and a $101.00 target price on the stock. Royal Bank Of Canada started coverage on AnaptysBio in a report on Thursday, September 14th. They issued an “outperform” rating and a $40.00 target price on the stock. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $35.00 price target on shares of AnaptysBio in a research note on Tuesday, September 12th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. AnaptysBio has a consensus rating of “Buy” and a consensus price target of $84.78.
TRADEMARK VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/04/goldman-sachs-group-inc-buys-new-position-in-anaptysbio-inc-anab.html.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc and related companies with MarketBeat.com's FREE daily email newsletter.